The global Clinical Contract Research Organization (CRO) Services Market is projected to grow from $54 billion in 2024 to $96 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.5%. CROs provide outsourced clinical trial services to pharmaceutical, biotechnology, and medical device companies, managing key aspects such as study design, patient recruitment, clinical monitoring, data management, regulatory compliance, and statistical analysis. The market is segmented by type (Phase I, II, III), application (oncology, infectious diseases, immunological disorders, vaccines, others), and region. Key players include Iqvia, Laboratory Corporation of America Holdings (LabCorp), PPD Inc. (part of Thermo Fisher Scientific), Syneos Health Inc., Wuxi Apptec Co., Ltd., Charles River Laboratories International, Inc., Parexel International Corporation, Pharmaron Beijing Co., Ltd., Icon Plc, Medpace Holdings, Inc., SGS SA, Frontage Holdings Corporation, Psi Cro AG, Bioagile Therapeutics Pvt. Ltd., Firma Clinical Research, Llc, Acculab Life Sciences, Novotech Health Holdings, KCR (formerly Kiecana Clinical Research), Linical Co., Ltd., and Advanced Clinical Direct. North America is the dominant region, while Asia-Pacific is the fastest-growing. The report analyzes market trends, competitive dynamics, and strategic initiatives to support industry expansion.

The Pharmacovigilance Market is projected to grow from USD 8.03 Bn in 2025 to USD 14.03 Bn by 2032 at a CAGR of 8.3%, driven by advancements in R&D, mergers, and regional expansions. The report analyzes market trends, segmentation by clinical trial phases, service providers, and geographic regions, while highlighting key players like Cognizant Technology Solutions, Laboratory Corporation of America Holdings, and IBM.

The Biomarker Clinical Phase Outsourcing Services Market is projected to grow from USD 6.9 billion in 2024 to USD 18.2 billion by 2033, with a CAGR of 11.4% between 2025 and 2033. The market is driven by demand for personalized medicine, R&D investments, and biomarker adoption in drug development. Key players include Covance Inc., ICON plc, and Eurofins Scientific, with North America dominating and Asia-Pacific emerging as a growth region due to cost-effective outsourcing hubs.

Hoth Therapeutics, a clinical-stage biopharma company, has partnered with ICON Clinical Research Ltd. to expand its Phase II clinical trial for HT-001, a treatment for skin toxicities associated with EGFRi. The trial will include additional clinical sites in the EU and is part of the company’s international strategy. Regulatory approval from three EU countries is expected, with the trial currently enrolling patients in the U.S. The study aims to evaluate HT-001’s efficacy, safety, and tolerability.

The report by Worldwide Market Reports analyzes the Rare Disease Clinical Trial Market, focusing on growth drivers, market constraints, opportunities, and challenges. It examines market size, revenue, production capacities, and compound annual growth rate (CAGR) to provide strategic insights for stakeholders. The report segments the market by trial phase, application, and region, highlighting trends in orphan drug development, gene therapy, and global expansion.